Literature DB >> 28703277

miRNAs and ovarian cancer: An overview.

Bornali Deb1, Arif Uddin2, Supriyo Chakraborty1.   

Abstract

Ovarian cancer (OC) is the sixth most common cancer in women globally. However, even with the advances in detection and therapeutics it still represents the most dangerous gynecologic malignancy in women of the industrialized countries. The discovery of micro-RNAs (miRNA), a small noncoding RNA molecule targeting multiple mRNAs and regulation of gene expression by triggering translation repression and/or RNA degradation, has revealed the existence of a new array for regulation of genes involved in cancer. This review summarizes the current knowledge regarding the role of miRNAs expression in OC. It also provides information about potential clinical relevance of circulating miRNAs for OC diagnosis, prognosis, and therapeutics. The identification of functional targets for miRNAs represents a major obstacle in our understanding of microRNA function in OC, but significant progress is being made. The better understanding of the role of microRNA expression in ovarian cancer may provide new array for the detection, diagnosis, and therapy of the OC.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  gynecologic malignancy; miRNA; ovarian cancer

Mesh:

Substances:

Year:  2017        PMID: 28703277     DOI: 10.1002/jcp.26095

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  63 in total

1.  miRNA-199a-5p suppresses proliferation and invasion by directly targeting NF-κB1 in human ovarian cancer cells.

Authors:  Xiaoxiao Liu; Baofeng Yao; Zhiming Wu
Journal:  Oncol Lett       Date:  2018-07-18       Impact factor: 2.967

2.  miR-1224-5p inhibits the proliferation and invasion of ovarian cancer via targeting SND1.

Authors:  Junrong Wang; Yubo Hu; Cong Ye; Junbao Liu
Journal:  Hum Cell       Date:  2020-05-14       Impact factor: 4.174

3.  LNA Inhibitor in microRNA miR-23b as a Potential Anti-proliferative Option in Human Hepatocellular Carcinoma.

Authors:  Zoya Najafi; Mohammadreza Sharifi; Gholamreza Javadi
Journal:  J Gastrointest Cancer       Date:  2020-03

4.  Transcriptomic analysis reveals tumor stage- or grade-dependent expression of miRNAs in serous ovarian cancer.

Authors:  Caglar Berkel; Ercan Cacan
Journal:  Hum Cell       Date:  2021-02-12       Impact factor: 4.174

5.  A novel regQTL-SNP and the risk of lung cancer: a multi-dimensional study.

Authors:  Yuhui Yu; Liping Mao; Zhounan Cheng; Xiaoqi Zhu; Jiahua Cui; Xiaoyu Fu; Jingwen Cheng; Yan Zhou; Anni Qiu; Yang Dong; Xun Zhuang; Yihua Lu; Yulong Lian; Tian Tian; Shuangshuang Wu; Minjie Chu
Journal:  Arch Toxicol       Date:  2021-10-01       Impact factor: 5.153

6.  microRNA-324-3p suppresses the aggressive ovarian cancer by targeting WNK2/RAS pathway.

Authors:  Fengjie Li; Zhen Liang; Yongqin Jia; Panyang Zhang; Kaijian Ling; Yanzhou Wang; Zhiqing Liang
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

7.  miR-122 and miR-197 expressions in hepatic carcinoma patients before and after chemotherapy and their effect on patient prognosis.

Authors:  Gang Zhan; Hui Jiang; Rui Yang; Kai Yang
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

8.  Circ_0003266 sponges miR-503-5p to suppress colorectal cancer progression via regulating PDCD4 expression.

Authors:  Caihong Wen; Xiaoqing Feng; Honggang Yuan; Yong Gong; Guangsheng Wang
Journal:  BMC Cancer       Date:  2021-03-16       Impact factor: 4.430

9.  MicroRNA-139-5p Regulates Fibrotic Potentials via Modulation of Collagen Type 1 and Phosphorylated p38 MAPK in Uterine Leiomyoma.

Authors:  So Hyun Ahn; Heeyon Kim; Inha Lee; Jae Hoon Lee; SiHyun Cho; Young Sik Choi
Journal:  Yonsei Med J       Date:  2021-08       Impact factor: 2.759

10.  miR-125a attenuates the malignant biological behaviors of cervical squamous cell carcinoma cells through Rad51.

Authors:  Zeping Liu; Jinchang Huang; Qiuju Jiang; Xiaoling Li; Xiaohui Tang; Shasha Chen; Liling Jiang; Genghua Fu; Sijun Liu
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.